Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. [electronic resource]
Producer: 20070921Description: 1080-2; author reply 1083 p. digitalISSN:- 0006-4971
- Aged
- Antimetabolites, Antineoplastic -- administration & dosage
- Azacitidine -- administration & dosage
- Chromosomes, Human, Pair 7
- Decitabine
- Dose-Response Relationship, Drug
- Female
- Humans
- Infusions, Intravenous
- Injections, Subcutaneous
- Leukocyte Count
- Monosomy
- Myelodysplastic Syndromes -- blood
- Randomized Controlled Trials as Topic
- Remission Induction
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't; Comment
There are no comments on this title.
Log in to your account to post a comment.